VOR Vor Biopharma

Vor to Participate in Two Upcoming Investor Conferences

Vor to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vor’s Chief Financial Officer, will be participating in two upcoming virtual investor conferences:

Stifel 2021 Virtual Healthcare Conference

Fireside Chat Date: Monday, November 15, 2021

Time: 4:00 PM ET

Evercore ISI 4th Annual HealthCONx Virtual Conference

Fireside Chat Date: Thursday, December 2, 2021

Time: 10:55 AM ET

A live webcast of both fireside chats can be accessed via the Investors section of the Company's website at . An archived replay of each webcast will also be available.

About Vor Biopharma

Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: .

Contacts:



Investors:

Chris Brinzey

ICR Westwicke



Media:

Sarah Spencer





EN
08/11/2021

Underlying

VORVor Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Confere...

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston, MA. Presentation: Monday, March 2, 2026 at 9:50am – 10:20 am ETLocation: Regis A live webcast and archived replay of the presentation will be remain available for a period of 90 days on the Company’s website at: About Vor B...

February 23, 2026 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Confe...

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Presentation: Tuesday, January 13, 2026 at 10:30am – 11:10 am PTLocation: The Westin St. Francis, Georgian Room A live webcast and archived replay of the presentation will be available on the Company’s website ...

January 6, 2026 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s...

Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company’s recently announced $150M PIPE financing, which included participation from both investors....

December 23, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Announces $150 Million Private Placement

Vor Bio Announces $150 Million Private Placement BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $150 million, before deducting any offering-relat...

December 15, 2025 1 EN
Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
SHOP SHOPIFY INC.
TRIP TRIPADVISOR INC.
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
OVID OVID THERAPEUTICS
AMZN AMAZON.COM INC.
BKNG BOOKING HOLDINGS INC.
LYFT LYFT
ZM ZOOM VIDEO COMMUNICATIONS INC. CLASS A
UBER UBER TECHNOLOGIES INC.
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
VRDN VIRIDIAN THERAPEUTICS INC
VOR VOR BIOPHARMA
FNMA FEDERAL NATIONAL MORTGAGE ASSOCIATION
ATXS ASTRIA THERAPEUTICS INC
YOU CLEAR SECURE INC
SLDB SOLID BIOSCIENCES INC
JBIO JADE BIOSCIENCES INC
IMA IMAGENEBIO INC.
KLAR KLARNA GROUP PLC
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
11/25/25 November 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch